2,2-Bis(methoxymethyl)propanoic acid | 161790-45-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,2-Bis(methoxymethyl)propanoic acid
• 英文别名: 3-methoxy-2-(methoxymethyl)-2-methylpropanoic acid；3-methoxy-2-methoxymethyl-2-methyl-propionic acid
• CAS: 161790-45-0
• 化学式: C₇H₁₄O₄
• 分子量: 162.186
• InChiKey: GHAPWJHHEAMCMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,2-Bis(methoxymethyl)propanoic acid 在 氯化亚砜 作用下， 反应 1.0h， 生成 2,2-bis(methoxymethyl)propionic acid chloride
  参考文献：
  名称：

  EP1437352

  摘要：

  公开号：
• 作为产物：
  描述：

  2,2-二羟甲基丙酸 、 碘甲烷 在 sodium hydride 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 21.0h， 生成 2,2-Bis(methoxymethyl)propanoic acid
  参考文献：
  名称：

  EP1437352

  摘要：

  公开号：

文献信息

• Benzimidazole derivatives
  申请人：——

  公开号：US20030236267A1

  公开（公告）日：2003-12-25

  This invention provides compounds which are represented by a general formula [I] 1 [in which X stands for hydrogen or halogen; B stands for halogen, cyano or optionally fluorine-substituted lower alkyl; D stands for a 3-10 membered aliphatic nitrogen-containing heterocyclic group; R 3 , R 4 and R 5 may be same or different, and each stands for hydrogen, lower alkyl optionally having substituent group(s) and the like; and a is 0 or 1]. These compounds exhibit high affinity to nociceptin receptors and whereby inhibit actions of nociceptin, and are useful as an analgesic, antiobestic, agent for ameliorating brain function, treating agents for Alzheimer's disease and dementia, and therapeutic agents for schizophrenia, neurodegenerative diseases, depression, diabetes insipidus, polyuria, hypotension and the like.

  这项发明提供了一些化合物，它们由一般式[I]1表示，其中X代表氢或卤素；B代表卤素、氰基或者可选的含氟低碳基；D代表一个3-10个成员的脂肪氮杂环基团；R3、R4和R5可能相同也可能不同，每个代表氢、可选的取代基的低碳基等；a为0或1。这些化合物表现出高亲和力对于痛觉受体，并抑制痛觉素的作用，因此可用作镇痛剂、抗肥胖剂、改善脑功能的药物、治疗阿尔茨海默病和痴呆症的药物、以及治疗精神分裂症、神经退行性疾病、抑郁症、尿崩症、多尿症、低血压等的治疗剂。
• TETRAHYDRONAPHTHALENE COMPOUNDS
  申请人：Hilpert Kurt

  公开号：US20110207815A1

  公开（公告）日：2011-08-25

  The invention relates to compounds of Formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , m and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.

  这项发明涉及到式（I）化合物，其中R1、R2、R3、R4、R5、m和n如描述中定义，并且涉及到这些化合物的药用盐。这些化合物可用作钙通道阻滞剂。
• Benzimidazone compound, process for producing the same, and use thereof
  申请人：——

  公开号：US20040248941A1

  公开（公告）日：2004-12-09

  The present invention relates to a compound represented by the following formula 1 wherein each symbol is as defined in the specification, or a salt thereof, which has superior stability to acid and which is a prodrug of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]- 1 H-benzimidazole. This compound (1) shows a superior anti-ulcer activity, a gastric acid secretion-suppressive action, a mucosa-protecting action, an anti- Helicobacter pylori action and the like in living organisms, (2) shows low toxicity, (3) shows superior stability to acid (which obviates the need to formulate an enteric-coated preparation, thereby lowering the cost, and reduces the size of preparation to facilitate swallowing for patients having difficulty in swallowing), (4) shows faster absorption than enteric-coated preparations (rapid expression of gastric acid secretion-suppressive action), and (5) is sustainable.

  本发明涉及以下式1所表示的化合物或其盐，其中每个符号如规范中所定义，该化合物具有优异的酸稳定性，并且是2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1H-苯并咪唑的前药。该化合物（1）在生物体内显示出优异的抗溃疡活性、抑制胃酸分泌作用、保护粘膜作用、抗幽门螺杆菌作用等，（2）显示出低毒性，（3）显示出优异的酸稳定性（无需配制肠溶涂层制剂，从而降低成本，并减小制剂的大小，以便于吞咽困难的患者），（4）显示出比肠溶涂层制剂更快的吸收速度（快速表达胃酸分泌抑制作用），并且（5）是可持续的。
• Monomer Compound, Process for Producing the Same, Polymer Thereof, and Water-Based Curable Composition
  申请人：Kobata Masami

  公开号：US20080053835A1

  公开（公告）日：2008-03-06

  The present invention provides an α-oxoamide group- and (meth)acryloyloxy group-containing monomer compound represented by Formula (I) wherein Y is a C 1-6 straight-chain alkylene group which may be substituted with a C 1-6 organic group, R 1 is a C 1-16 organic group, R 2 is a hydrogen atom or a C 1-8 organic group, and R 3 is a hydrogen atom or a methyl group; a production process therefor; a polymer thereof; and an aqueous curable composition containing the polymer.

  本发明提供了一种α-氧酰胺基和（甲基）丙烯酰氧基含有的单体化合物，其化学式为（I），其中Y为C1-6直链烷基，可以被C1-6有机基替代，R1为C1-16有机基，R2为氢原子或C1-8有机基，R3为氢原子或甲基；其制备方法；其聚合物；以及含有该聚合物的水性固化组合物。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF
  申请人：NAKAI Hisao

  公开号：US20100063104A1

  公开（公告）日：2010-03-11

  It is intended to provide a compound represented by the formula (I): wherein all the symbols are as defined in the description; which has a p38 MAP kinase inhibitory activity, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. The compound of the invention is useful for preventing or treating a disease in which the abnormal production of a cytokine such as an inflammatory cytokine or a chemokine or overreaction to them is considered to be involved in the cause and aggravation of pathological conditions, in other words, an inflammatory disease, a respiratory disease, a cardiovascular disease, a central nervous system disease or the like, which is a cytokine-mediated disease.

  本发明旨在提供一种由公式（I）表示的化合物：其中所有符号如描述中所定义的；其具有p38 MAP激酶抑制活性，其盐，其N-氧化物，其溶剂合物或其前药。本发明的化合物可用于预防或治疗疾病，其中被认为异常产生细胞因子如炎症性细胞因子或趋化因子或对它们过度反应与病理情况的发生和加重有关，换句话说，是细胞因子介导的疾病，例如炎症性疾病，呼吸系统疾病，心血管疾病，中枢神经系统疾病或类似疾病。